| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 15, 2006
From the Department of Anesthesiology and Critical Care Medicine (C.W.H., Jr), Johns Hopkins University Medical School, Baltimore, Md; the Departments of Psychiatry (K.F., T.H., S.B.) and Neurology (R.F., A.N.), the Cardiovascular Division, Department of Medicine (B.B., V.G.D.-R.), the Department of Anesthesiology (B.T.), and the Division of Biostatistics, Department of Medicine (D.D., K.B.S.), Washington University School of Medicine, St. Louis, Mo. * To whom correspondence should be addressed. E-mail: chogue2{at}jhmi.edu.
Background and Purpose--Neurocognitive dysfunction is an important source of patient morbidity and mortality after cardiac surgery that may disproportionately affect postmenopausal women. 17 Methods--One hundred seventy-four postmenopausal women not on estrogen replacement therapy who were undergoing primary coronary artery bypass graft surgery and/or valve surgery with cardiopulmonary bypass were prospectively randomized to receive in a double-blinded manner either 17 Results--There were no differences in the frequency of neurocognitive dysfunction (primary outcome) between patients randomized to perioperative 17 Conclusions--Perioperative treatment with 17
Revised on January 19, 2007
Accepted on January 22, 2007
Neurocognitive Outcomes Are Not Improved by 17
Charles W. Hogue Jr MD*;
-Estradiol in Postmenopausal Women Undergoing Cardiac Surgery
-Estradiol limits the extent of ischemic neuronal injury in a variety of experimental models. The purpose of this study was to evaluate whether perioperative administration of 17
-estradiol to postmenopausal women reduces the frequency of neurocognitive dysfunction after cardiac surgery.
-estradiol or placebo beginning the day before surgery and continuing for 5 days postoperatively. The patients were evaluated before and after surgery with the National Institutes of Health Stroke Scale and a psychometric test battery.
-estradiol (n=86) and those randomized to placebo (n=88) 4 to 6 weeks after surgery (17
-estradiol, 22.4% versus placebo, 21.4%, P=0.45). The mean scores on tests of psychomotor speed were worse in women in the 17
-estradiol group than in the placebo group at the 4- to 6-week (P=0.005) postoperative testing sessions.
-estradiol did not result in improved neurocognitive outcomes in postmenopausal women undergoing cardiac surgery.
This article has been cited by other articles:
![]() |
C. W. Hogue Jr, R. Fucetola, T. Hershey, A. Nassief, S. Birge, V. G. Davila-Roman, B. Barzilai, B. Thomas, K. B. Schechtman, and K. Freedland The Role of Postoperative Neurocognitive Dysfunction on Quality of Life for Postmenopausal Women 6 Months After Cardiac Surgery Anesth. Analg., July 1, 2008; 107(1): 21 - 28. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Gorelick and J. V. Bowler Advances in Vascular Cognitive Impairment 2007 Stroke, February 1, 2008; 39(2): 279 - 282. [Full Text] [PDF] |
||||
![]() |
Can Estrogen Improve Postsurgical Neurocognitive Outcomes? Journal Watch Women's Health, July 19, 2007; 2007(719): 5 - 5. [Full Text] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |